Three Year Analysis Of Treatment Efficacy, Cosmesis, And Toxicity Support Use Of The Hologic Mammosite Radiation Therapy System
Feb 26th 2008Drug InformationBreast Cancer
Hologic, Inc. (Nasdaq: HOLX) a diversified medical technologies company specializing in imaging systems, diagnostics, and interventional devices dedicated to serving the healthcare needs of women, announced the publication of a study evaluating the Hologic MammoSite(R) Radiation Therapy System (RTS), one-, two- and three-years after treatment. The study by Frank A. Vicini, M.D.
More: continued here
No Comments »
Leave a Reply
You must be logged in to post a comment.
